Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).

✍ Scribed by Buchler, Tomas; Bortlicek, Zbynek; Poprach, Alexandr; Kubackova, Katerina; Kiss, Igor; Zemanova, Milada; Fiala, Ondrej; Dusek, Ladislav; Vyzula, Rostislav; Melichar, Bohuslav

• Book ID: 122221139
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 327 KB
• Volume: 32
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2013.12.007